PegBio (2565) Announces Filing for H Share Full Circulation

Bulletin Express11-28

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited have stated that they assume no responsibility for the contents of PegBio Co., Ltd.’s (2565) announcement.

According to official information, PegBio Co., Ltd. submitted an application to the China Securities Regulatory Commission (CSRC) on November 28, 2025, under the “Guidelines on Application for ‘Full Circulation’ of Domestic Unlisted Shares of H-share Companies” (CSRC Announcement [2023] No. 50). This filing concerns the proposed conversion of 101,702,051 unlisted shares (approximately 26.35% of the total issued shares) on a one-for-one basis into H shares. Following approval from the CSRC and the Stock Exchange of Hong Kong, the newly converted shares will be listed on the Main Board of the Stock Exchange.

The company has indicated that no further shareholders’ meeting is required for this proposed conversion and listing. It has not yet received CSRC approval, and details of the implementation plan are pending finalization. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138120213?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-28 16:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138120213","market":"us","top_or_hot":-1,"title":"PegBio (2565) Announces Filing for H Share Full Circulation","media":"Bulletin Express","content":"<p>Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited have stated that they assume no responsibility for the contents of PegBio Co., Ltd.’s (2565) announcement.</p>\n<p>According to official information, PegBio Co., Ltd. submitted an application to the China Securities Regulatory Commission (CSRC) on November 28, 2025, under the “Guidelines on Application for ‘Full Circulation’ of Domestic Unlisted Shares of H-share Companies” (CSRC Announcement [2023] No. 50). This filing concerns the proposed conversion of 101,702,051 unlisted shares (approximately 26.35% of the total issued shares) on a one-for-one basis into H shares. Following approval from the CSRC and the Stock Exchange of Hong Kong, the newly converted shares will be listed on the Main Board of the Stock Exchange.</p>\n<p>The company has indicated that no further shareholders’ meeting is required for this proposed conversion and listing. It has not yet received CSRC approval, and details of the implementation plan are pending finalization. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PegBio (2565) Announces Filing for H Share Full Circulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPegBio (2565) Announces Filing for H Share Full Circulation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-28 16:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited have stated that they assume no responsibility for the contents of PegBio Co., Ltd.’s (2565) announcement.</p>\n<p>According to official information, PegBio Co., Ltd. submitted an application to the China Securities Regulatory Commission (CSRC) on November 28, 2025, under the “Guidelines on Application for ‘Full Circulation’ of Domestic Unlisted Shares of H-share Companies” (CSRC Announcement [2023] No. 50). This filing concerns the proposed conversion of 101,702,051 unlisted shares (approximately 26.35% of the total issued shares) on a one-for-one basis into H shares. Following approval from the CSRC and the Stock Exchange of Hong Kong, the newly converted shares will be listed on the Main Board of the Stock Exchange.</p>\n<p>The company has indicated that no further shareholders’ meeting is required for this proposed conversion and listing. It has not yet received CSRC approval, and details of the implementation plan are pending finalization. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1138120213","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138120213","pubTimestamp":1764319717,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited have stated that they assume no responsibility for the contents of PegBio Co., Ltd.’s (2565) announcement....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"培格生物(2565)宣布申请H股全流通","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited have stated that they assume no responsibility for the contents of PegBio Co., Ltd.’s (2565) announcement.\nAccording to official information, PegBio Co., Ltd. submitted an application to the China Securities Regulatory Commission (CSRC) on November 28, 2025, under the “Guidelines on Application for ‘Full Circulation’ of Domestic Unlisted Shares of H-share Companies” (CSRC Announcement [2023] No. 50). This filing concerns the proposed conversion of 101,702,051 unlisted shares (approximately 26.35% of the total issued shares) on a one-for-one basis into H shares. Following approval from the CSRC and the Stock Exchange of Hong Kong, the newly converted shares will be listed on the Main Board of the Stock Exchange.\nThe company has indicated that no further shareholders’ meeting is required for this proposed conversion and listing. It has not yet received CSRC approval, and details of the implementation plan are pending finalization. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138120213","isCrawlerRequest":true}